Insider Selling: Roivant Sciences (NASDAQ:ROIV) CAO Sells $384,073.06 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Jennifer Humes sold 13,538 shares of Roivant Sciences stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the transaction, the chief accounting officer owned 84,191 shares in the company, valued at $2,388,498.67. The trade was a 13.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $28.21 on Monday. The stock has a market capitalization of $20.19 billion, a price-to-earnings ratio of -24.11 and a beta of 1.20. The stock’s fifty day simple moving average is $27.40 and its 200 day simple moving average is $22.74. Roivant Sciences Ltd. has a 52-week low of $9.57 and a 52-week high of $30.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. SBI Securities Co. Ltd. grew its holdings in shares of Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after buying an additional 1,166 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after buying an additional 1,148 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares in the last quarter. Bessemer Group Inc. grew its stake in Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in Roivant Sciences in the fourth quarter valued at about $47,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on ROIV shares. HC Wainwright lifted their target price on Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Sanford C. Bernstein started coverage on Roivant Sciences in a report on Friday, March 20th. They set an “outperform” rating and a $35.00 price target on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. The Goldman Sachs Group lifted their price target on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, Leerink Partners lifted their price target on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $29.50.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.